Monitoring of inflammation in patients on dialysis: Forewarned is forearmed

Nature Reviews Nephrology

Volumn 7, Issue 3, 2011, Pages 166-176

  Meuwese, Christiaan L ^a   Stenvinkel, Peter ^b   Dekker, Friedo W ^a   Carrero, Juan J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR5; COLECALCIFEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; INTERLEUKIN 6; PENTOXIFYLLINE; SEVELAMER; STATIN; TUMOR NECROSIS FACTOR;

CHRONIC KIDNEY DISEASE; COMORBIDITY; DIALYSIS; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; IMMUNE SYSTEM; INFLAMMATION; OUTCOME ASSESSMENT; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UREMIA;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 79952120601     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.2     Document Type: Review

References (116)

1. Foley, R. N. et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J. Am. Soc. Nephrol. 16, 489-495 (2005). (Pubitemid 41725146)
2. vanholder, R. et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol. Dial. Transplant. 20, 1048-1056 (2005). (Pubitemid 40862092)
3. de Jager, D. J. et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302, 1782-1789 (2009).
4. Stenvinkel, P. et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 55, 1899-1911 (1999). (Pubitemid 29197978)
5. Shlipak, M. G. et al. Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA 293, 1737-1745 (2005).
6. Kimmel, P. L. et al. Immunologic function and survival in hemodialysis patients. Kidney Int. 54, 236-244 (1998). (Pubitemid 28288040)
7. Korevaar, J. C. et al. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J. Am. Soc. Nephrol. 15, 2916-2922 (2004). (Pubitemid 41103401)
8. Memoli, B. Cytokine production in hemodialysis. Blood Purif. 17, 149-158 (1999).
9. Luger, A., Kovarik, J., Stummvoll, H. K., Urbanska, A. & Luger, T. A. Blood-membrane interaction in hemodialysis leads to increased cytokine production. Kidney Int. 32, 84-88 (1987). (Pubitemid 17094502)
10. Szeto, C. C. et al. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin. J. Am. Soc. Nephrol. 3, 431-436 (2008).
11. Carrero, J. J., Yilmaz, M. I., Lindholm, B. & Stenvinkel, P. Cytokine dysregulation in chronic kidney disease: How can we treat it? Blood Purif. 26, 291-299 (2008). (Pubitemid 351748064)
12. Iseki, K., Tozawa, M., Yoshi, S. & Fukiyama, K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol. Dial. Transplant. 14, 1956-1960 (1999). (Pubitemid 29358894)
13. Wanner, C. & Metzger, T. C-reactive protein a marker for all-cause and cardiovascular mortality in hemodialysis patients. Nephrol. Dial. Transplant. 17 (Suppl. 8), 29-32 (2002). (Pubitemid 34918876)
14. Pecoits-Filho, R., Barany, P., Lindholm, B., Heimburger, O. & Stenvinkel, P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol. Dial. Transplant. 17, 1684-1688 (2002). (Pubitemid 35012175)
15. Panichi, v. et al. Chronic inflammation and mortality in hemodialysis: Effect of different renal replacement therapies. Results from the RISCAvID study. Nephrol. Dial. Transplant. 23, 2337-2343 (2008). (Pubitemid 351957592)
16. Kawaguchi, T. et al. C-reactive protein and mortality in hemodialysis patients: The dialysis outcomes and practice patterns study (DOPPS). Nephron Clin. Pract. 117, c167-c178 (2010).
17. Yilmaz, M. I., Carrero, J. J., Axelsson, J., Lindholm, B. & Stenvinkel, P. Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: Sources and consequences. Clin. Nephrol. 68, 1-9 (2007). (Pubitemid 47045486)
18. Snaedal, S. et al. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: Implications for patient survival. Am. J. Kidney Dis. 53, 1024-1033 (2009).
19. Koj, A. Initiation of acute phase response and synthesis of cytokines. Biochim. Biophys. Acta 1317, 84-94 (1996). (Pubitemid 26388776)
20. Baigrie, R. J., Lamont, P. M., Kwiatkowski, D., Dallman, M. J. & Morris, P. J. Systemic cytokine response after major surgery. Br. J. Surg. 79, 757-760 (1992).
21. Hatada, T. & Miki, C. Nutritional status and postoperative cytokine response in colorectal cancer patients. Cytokine 12, 1331-1336 (2000).
22. Peri, G. et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 102, 636-641 (2000). (Pubitemid 30640663)
23. De Beer, F. C. et al. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br. Heart J. 47, 239-243 (1982). (Pubitemid 12179920)
24. Pepys, M. B. & Hirschfield, G. M. C-reactive protein, a critical update. J. Clin. Invest. 111, 1805-1812 (2003).
25. vigushin, D. M., Pepys, M. B. & Hawkins, P. N. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J. Clin. Invest. 91, 1351-1357 (1993). (Pubitemid 23127332)
26. Zacho, J. et al. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med. 359, 1897-1908 (2008).
27. Zhang, L. et al. C-reactive protein haplotype predicts serum C-reactive protein levels but not cardiovascular disease risk in a dialysis cohort. Am. J. Kidney Dis. 49, 118-126 (2007). (Pubitemid 44932197)
28. Lee, S. A. et al. Intra-individual variation of plasma adipokine levels and utility of single measurement of these biomarkers in populationbased studies. Cancer Epidemiol. Biomarkers Prev. 16, 2464-2470 (2007).
29. Macy, E. M., Hayes, T. E. & Tracy, R. P. variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications. Clin. Chem. 43, 52-58 (1997). (Pubitemid 27024390)
30. Ockene, I. S. et al. variability and classification accuracy of serial high-sensitivity C-reactiveprotein measurements in healthy adults. Clin. Chem. 47, 444-450 (2001). (Pubitemid 32222458)
31. Bogaty, P. et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch. Intern. Med. 165, 221-226 (2005).
32. Danesh, J. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387-1397 (2004). (Pubitemid 38419992)
33. Koenig, W. et al. Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: The MONICA Augsburg studies, 1984 and 1987. Am. J. Epidemiol. 158, 357-364 (2003). (Pubitemid 41288803)
34. vozarova, B. et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes. Res. 9, 414-417 (2001). (Pubitemid 33603868)
35. Koenig, W. et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middleaged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99, 237-242 (1999). (Pubitemid 29056365)
36. Fox, E. R. et al. Epidemiology, heritability, and genetic linkage of C-reactive protein in African Americans (from the Jackson Heart Study). Am. J. Cardiol. 102, 835-841 (2008).
37. Khera, A. et al. Race and gender differences in C-reactive protein levels. J. Am. Coll. Cardiol. 46, 464-469 (2005). (Pubitemid 41040287)
38. Nasermoaddeli, A., Sekine, M. & Kagamimori, S. Intra-individual variability of high-sensitivity C-reactive protein: Age-related variations over time in Japanese subjects. Circ. J. 70, 559-563 (2006).
39. Carrero, J. J. Gender differences in chronic kidney disease: Underpinnings and therapeutic implications. Kidney Blood Press. Res. 33, 383-392 (2010).
40. Picotte, M., Campbell, C. G. & Thorland, W. G. Day-to-day variation in plasma interleukin-6 concentrations in older adults. Cytokine 47, 162-165 (2009).
41. van Tellingen, A. et al. Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int. 62, 632-638 (2002). (Pubitemid 34779778)
42. Kaysen, G. A., Dubin, J. A., Muller, H. G., Rosales, L. M. & Levin, N. W. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. Kidney Int. 58, 346-352 (2000). (Pubitemid 30429881)
43. Tsirpanlis, G. et al. Exploring inflammation in hemodialysis patients: Persistent and superimposed inflammation. A longitudinal study. Kidney Blood Press. Res. 27, 63-70 (2004). (Pubitemid 38594557)
44. Tsirpanlis, G. et al. The variability and accurate assessment of microinflammation in hemodialysis patients. Nephrol. Dial. Transplant. 19, 150-157 (2004). (Pubitemid 38072626)
45. Landray, M. J. et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: The chronic renal impairment in Birmingham (CRIB) study. Am. J. Kidney Dis. 43, 244-253 (2004). (Pubitemid 38146322)
46. Miyata, T. et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with endstage renal failure. Kidney Int. 51, 1170-1181 (1997). (Pubitemid 27186543)
47. Panichi, v. et al. C-reactive protein in patients on chronic hemodialysis with different techniques and different membranes. Biomed. Pharmacother. 60, 14-17 (2006). (Pubitemid 41821213)
48. Stigant, C. E., Djurdjev, O. & Levin, A. C-reactive protein levels in patients on maintenance hemodialysis: Reliability and reflection on the utility of single measurements. Int. Urol. Nephrol. 37, 133-140 (2005). (Pubitemid 41236259)
49. Ortega, O. et al. Strict volume control and longitudinal changes in cardiac biomarker levels in hemodialysis patients. Nephron Clin. Pract. 113, c96-c103 (2009).
50. Shafi, T. et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: The Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am. J. Kidney Dis. 56, 348-358 (2010).
51. Kolz, M. et al. DNA variants, plasma levels and variability of C-reactive protein in myocardial infarction survivors: Results from the AIRGENE study. Eur. Heart J. 29, 1250-1258 (2008). (Pubitemid 351768118)
52. Bennermo, M. et al. Genetic predisposition of the interleukin-6 response to inflammation: Implications for a variety of major diseases? Clin. Chem. 50, 2136-2140 (2004). (Pubitemid 39425852)
53. Girndt, M. et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int. 62, 949-955 (2002). (Pubitemid 35316724)
54. Menon, v. et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 68, 766-772 (2005). (Pubitemid 43323132)
55. Ortega, O. et al. Significance of high C-reactive protein levels in pre-dialysis patients. Nephrol. Dial. Transplant. 17, 1105-1109 (2002). (Pubitemid 34746216)
56. Panichi, v. et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in hemodialysis patients. Nephrol. Dial. Transplant. 19, 1154-1160 (2004). (Pubitemid 38628135)
57. Wanner, C., Zimmermann, J., Schwedler, S. & Metzger, T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int. 61, S99-S102 (2002). (Pubitemid 34534168)
58. Park, C. W. et al. Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am. J. Kidney Dis. 40, 1230-1239 (2002). (Pubitemid 35403135)
59. Tarakcioglu, M., Erbagci, A. B., Usalan, C., Deveci, R. & Kocabas, R. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines. Mediators Inflamm. 12, 15-19 (2003). (Pubitemid 36566700)
60. Boehme, M. et al. Pentraxin 3 is elevated in hemodialysis patients and is associated with cardiovascular disease. Nephrol. Dial. Transplant. 22, 2224-2229 (2007). (Pubitemid 47244700)
61. Hasuike, Y. et al. Interleukin-6 is a predictor of mortality in stable hemodialysis patients. Am. J. Nephrol. 30, 389-398 (2009).
62. Kimmel, P. L. et al. Immunologic function and survival in hemodialysis patients. Kidney Int. 54, 236-244 (1998). (Pubitemid 28288040)
63. Kato, A., Takita, T., Furuhashi, M., Maruyama, Y. & Hishida, A. Comparison of serum albumin, C-reactive protein and carotid atherosclerosis as predictors of 10-year mortality in hemodialysis patients. Hemodial. Int. 14, 226-232 (2010).
64. Zoccali, C., Tripepi, G. & Mallamaci, F. Dissecting inflammation in ESRD: Do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J. Am. Soc. Nephrol. 17 (12 Suppl. 3), S169-S173 (2006). (Pubitemid 44865244)
65. Han, S. H. et al. Elevated cardiac troponin T predicts cardiovascular events in asymptomatic continuous ambulatory peritoneal dialysis patients without a history of cardiovascular disease. Am. J. Nephrol. 29, 129-135 (2009).
66. Herzig, K. A. et al. Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J. Am. Soc. Nephrol. 12, 814-821 (2001). (Pubitemid 32246710)
67. Wang, A. Y. et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J. Am. Soc. Nephrol. 15, 2186-2194 (2004). (Pubitemid 39031357)
68. Ikizler, T. A., Wingard, R. L., Harvell, J., Shyr, Y. & Hakim, R. M. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. Kidney Int. 55, 1945-1951 (1999). (Pubitemid 29197983)
69. Tripepi, G., Mallamaci, F. & Zoccali, C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J. Am. Soc. Nephrol. 16 (Suppl. 1), S83-S88 (2005). (Pubitemid 41725091)
70. Honda, H. et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am. J. Kidney Dis. 47, 139-148 (2006). (Pubitemid 41828276)
71. Pereira, B. J. et al. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 45, 890-896 (1994).
72. Herbelin, A., Nguyen, A. T., Zingraff, J., Urena, P. & Descamps-Latscha, B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int. 37, 116-125 (1990). (Pubitemid 20023775)
73. Ridker, P. M. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344, 1959-1965 (2001). (Pubitemid 32568149)
74. Nascimento, M. M. et al. The prognostic impact of fluctuating levels of C-reactive protein in Brazilian hemodialysis patients: A prospective study. Nephrol. Dial. Transplant. 19, 2803-2809 (2004). (Pubitemid 39480976)
75. Dekker, F. W., de Mutsert, R., van Dijk, P. C., Zoccali, C. & Jager, K. J. Survival analysis: Time-dependent effects and time-varying risk factors. Kidney Int. 74, 994-997 (2008).
76. den Elzen, W. P., van Manen, J. G., Boeschoten, E. W., Krediet, R. T. & Dekker, F. W. The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis. Nephrol. Dial. Transplant. 21, 1588-1595 (2006). (Pubitemid 43834640)
77. Ridker, P. M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: Moving an inflammatory hypothesis toward consensus. J. Am. Coll. Cardiol. 49, 2129-2138 (2007). (Pubitemid 46783865)
78. Platz, E. A. et al. Intra-individual variation in serum C-reactive protein over 4 years: An implication for epidemiologic studies. Cancer Causes Control. 21, 847-851 (2010).
79. Meuwese, C. L. et al. Trimestral variation patterns of C-reactive protein, interleukin-6 and tumor necrosis factor-a are similarly associated with survival in hemodialysis patients. Nephrol. Dial. Transplant. doi:10.1093/ndt/gfq557.
80. Ates, K., Ates, A., Ekmekci, Y. & Nergizoglu, G. The time course of serum C-reactive protein is more predictive of mortality than its baseline level in peritoneal dialysis patients. Perit. Dial. Int. 25, 256-268 (2005). (Pubitemid 40724206)
81. Kim, B. S. et al. Persistent elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained onhemodialysis. Am. J. Nephrol. 25, 189-195 (2005).
82. Rao, M. et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 45, 324-333 (2005). (Pubitemid 40431059)
83. Levitt, H., Smith, K. G. & Rosner, M. H. variability in calcium, phosphorus, and parathyroid hormone in patients on hemodialysis. Hemodial. Int. 13, 518-525 (2009).
84. Yang, W. et al. Hemoglobin variability and mortality in ESRD. J. Am. Soc. Nephrol. 18, 3164-3170 (2007). (Pubitemid 350223976)
85. Koulouridis, E. et al. Homocysteine and C-reactive protein levels in hemodialysis patients. Int. Urol. Nephrol. 33, 207-215 (2001). (Pubitemid 34575368)
86. Raj, D. S. et al. Coordinated increase in albumin, fibrinogen, and muscle protein synthesis during hemodialysis: Role of cytokines. Am. J. Physiol. Endocrinol. Metab. 286, E658-E664 (2004). (Pubitemid 38374965)
87. Ciaccio, M. et al. Changes in serum fetuin-A and inflammatory markers levels in end-stage renal disease (ESRD): Effect of a single session hemodialysis. Clin. Chem. Lab. Med. 46, 212-214 (2008).
88. Schulze, C. et al. Reduced expression of systemic proinflammatory cytokines after offpump versus conventional coronary artery bypass grafting. Thorac. Cardiovasc. Surg. 48, 364-369 (2000). (Pubitemid 32004947)
89. Meuwese, C. L. et al. variations in C-reactive protein during a single hemodialysis session do not associate with mortality. Nephrol. Dial. Transplant. 25, 3717-3723 (2010).
90. Pearson, T. A. et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499-511 (2003). (Pubitemid 36158056)
91. Carrero, J. J. & Stenvinkel P. Inflammation in endstage renal disease-what have we learned in 10 years? Semin. Dial. 23, 498-509 (2010).
92. Simmons, E. M. et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 65, 1357-1365 (2004). (Pubitemid 38406974)
93. Ducloux, D. et al. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int. 62, 1417-1422 (2002).
94. Wanner, C., Richardson, D., Fouque, D. & Stenvinkel, P. OPTA-Influence of inflammation/ infection on anemia therapy in hemodialysis patients. Nephrol. Dial. Transplant. 22 (Suppl. 3), iii7-iii12 (2007).
95. Stenvinkel, P. et al. Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage? Kidney Int. 62, 1791-1798 (2002). (Pubitemid 35286288)
96. Kawaguchi, T. et al. C-reactive protein and mortality in hemodialysis patients: The dialysis outcomes and practice patterns study (DOPPS). Nephron Clin. Pract. 117, c167-c178 (2010).
97. Zimmermann, J., Herrlinger, S., Pruy, A., Metzger, T. & Wanner, C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 55, 648-658 (1999). (Pubitemid 29082891)
98. Mallamaci, F., Tripepi, G., Cutrupi, S., Malatino, L. S. & Zoccali, C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int. 67, 2330-2337 (2005). (Pubitemid 41623394)
99. Tripepi, G., Jager, K. J., Dekker, F. W. & Zoccali, C. Statistical methods for the assessment of prognostic biomarkers (Part II): Calibration and re-classification. Nephrol. Dial. Transplant. 25, 1402-1405 (2010).
100. Tripepi, G., Jager, K. J., Dekker, F. W. & Zoccali, C. Statistical methods for the assessment of prognostic biomarkers (Part I): Discrimination. Nephrol. Dial. Transplant. 25, 1399-1401 (2010).
101. Blankenberg, S. et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: The MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 121, 2388-2397 (2010).
102. Carrero, J. J. & Stenvinkel, P. Persistent inflammation as a catalyzt for other risk factors in chronic kidney disease: A hypothesis proposal. Clin. J. Am. Soc. Nephrol. 4 (Suppl. 1), S49-S55 (2009).
103. Gunnell, J., Yeun, J. Y., Depner, T. A. & Kaysen, G. A. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am. J. Kidney Dis. 33, 63-72 (1999). (Pubitemid 29031210)
104. Wei, M., Bargman, J. M. & Oreopoulos, D. G. Factors related to erythropoietin hyporesponsiveness in patients on chronic peritoneal dialysis. Int. Urol. Nephrol. 39, 935-940 (2007). (Pubitemid 47365410)
105. Matias, P. J. et al. Cholecalciferol supplementation in hemodialysis patients: Effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin. J. Am. Soc. Nephrol. 5, 905-911 (2010).
106. Caglar, K. et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin. J. Am. Soc. Nephrol. 3, 61-68 (2008).
107. Yamamoto, D., Takai, S., Hirahara, I. & Kusano, E. Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy. Clin. Chim. Acta 411, 762-764 (2010).
108. Perkins, R. M. et al. Effect of pentoxifylline on GFR decline in CKD: A pilot, double-blind, randomized, placebo-controlled trial. Am. J. Kidney Dis. 53, 606-616 (2009).
109. Fellstrom, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395-1407 (2009).
110. Muntinghe, F. L. et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J. Am. Soc. Nephrol. 20, 1641-1649 (2009).
111. Muntinghe, F. L., Carrero, J. J., Navis, G. & Stenvinkel, P. TNF-a levels are not increased in inflamed patients carrying the CCR5 deletion 32. Cytokine 53, 16-18 (2011).
112. Smolen, J. S. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 371, 987-997 (2008). (Pubitemid 351392039)
113. Scheinecker, C., Redlich, K. & Smolen, J. S. Cytokines as therapeutic targets: Advances and limitations. Immunity 28, 440-444 (2008). (Pubitemid 351467046)
114. Don, B. R. et al. The pharmacokinetics of etanercept in patients with end-stage renal disease on hemodialysis. J. Pharm. Pharmacol. 57, 1407-1413 (2005). (Pubitemid 350066982)
115. Don, B. R. et al. The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. Clin. Nephrol. 73, 431-438 (2010).
116. Cheung, A. K. et al. Effects of high-flux hemodialysis on clinical outcomes: Results of the HEMO study. J. Am. Soc. Nephrol. 14, 3251-3263 (2003). (Pubitemid 37509301)